Markets
Employees of Sunrun, nation's largest rooftop solar installer lift panels onto a roof
Sunrun employees carry panels into position (Brian van der Brug/Getty Images)

Sunrun shares shine after big Q2 earnings beat and record energy storage demand

The energy storage and solar panel provider crushed Wall Street’s estimates as new installations soared.

Sunrun soared 30% Thursday after the solar company reported a surprise second-quarter profit and record customer demand for its energy storage systems.

Earnings per share hit $1.07, a sharp beat compared to Wall Street’s expected $0.06 loss. Revenue also topped forecasts, coming in at $569.3 million versus the $559.4 million consensus. 

Storage was the star: Sunrun hit a new high for storage attachment, with 70% of new customers adding batteries — up from 54% a year ago. Overall, customer additions with storage grew 50% annually. Last year, Sunrun accounted for one in every five US rooftop solar systems.

Sunrun’s blowout results follow a similarly sunny report last week from rival First Solar, which also beat Q2 estimates and raised its full-year outlook despite a looming timeline for US clean energy tax credits. 

Wall Street thinks the road ahead could be even brighter: JPMorgan reiterated its “overweight” (buy) rating on the stock and raised its price target to $20 from $16, citing strong Q2 results, record storage attachment, and lower costs. It also added that Sunrun could sustain profits post-2028, even without tax credits, thanks to cost cuts, grid revenue, and rising utility prices.

Sunrun shares are now positive on the year, up about 17% year to date.

More Markets

See all Markets
markets

Canopy rallies after CEO stock purchase

Canopy Growth rallied on Wednesday after its CEO, Luc Mongeau, disclosed an unplanned stock purchase on Tuesday.

Mongeau, who joined Canopy from Mars in January, bought 27,469 shares at CA$1.84. The buy is worth about US$36,259.

It has been a tumultuous time for cannabis stocks, as the market in Canada (where Canopy is located) stagnates and cannabis reform in the US has yet to move forward.

markets

Robinhood, new S&P 500 leader, the subject of favorable analyst chatter

Robinhood Markets briefly touched a new all-time intraday high in early trading after the newly minted — and now top-performing — member of the the S&P 500 received some favorable write-ups from Wall Street analysts.

(Robinhood Markets Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions. I own stock as part of my compensation.)

Piper Sandler analysts highlighted momentum in the company’s prediction markets business thanks to the rollout of contracts on college and profession football, noting that the event contracts business was running at a $200 million annualized rate so far in September. They raised their price target on the shares to $140 from $120.

“Prediction Markets (aka event contracts) present significant upside opportunity for Robinhood,” Piper Sandler’s Patrick Moley wrote.

Elsewhere, Citi analysts raised their Q3 and full-year 2025 estimates and upped their price target on the shares to $135, but kept a “neutral” rating on the stock.

“While HOOD continues to see solid momentum across the platform, we believe the stock is pricing in much of the growth potential in our view. Given current valuations and where we are in the retail cycle (closer to the highs than the lows from an activity perspective from our viewpoint), we prefer to wait for a more reasonable entry point at present.”

The stock has clearly had a heck of a run.

Through yesterday’s close, Robinhood was up nearly 240% in 2025. Since it was added to the S&P 500 on Monday, it’s now the top performer among the blue chips, trouncing previous leaders Seagate Technology Holdings and Palantir.

markets

UniQure surges after encouraging trial results for Huntington’s treatment

UniQure rose more than 150% in early trading Wednesday after it released trial results that showed its experimental gene therapy for Huntington’s disease slowed its progression by 75% after three years.

The treatment, AMT-130, is a one-time treatment for Huntington’s, a genetic brain disease that degrades cognitive function and muscle control. There is currently no cure for the disease.

UniQure said it plans to submit the treatment for approval to the Food and Drug Administration in the first quarter of 2026, meaning it could become available to patients later that year. The company currently makes nearly all of its revenue from gene therapies that treat hemophilia.

Halo of the sun

A tiny UK company is showing how easy it is to get an (undeserved?) Nvidia halo effect

Step 1: join a free Nvidia program. Step 2: watch stock go up. Step 3: watch stock go down.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.